(Q42668717)

4 November 2017

title

Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series (English)

1 reference

obsessive-compulsive disorder

4 November 2017

main subject

1 reference

inferred from title

author name string

Michael Van Ameringen

1

1 reference

4 November 2017

Catherine Mancini

2

1 reference

4 November 2017

Beth Patterson

3

1 reference

4 November 2017

Mark Bennett

4

1 reference

4 November 2017

publication date

1 January 2006

1 reference

4 November 2017

published in

Depression and Anxiety

1 reference

4 November 2017

volume

23

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

1-5

1 reference

Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.

4 November 2017

cites work

1 reference

7 January 2021

Topiramate titration and tolerability

1 reference

7 January 2021

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

7 January 2021

Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

7 January 2021

Valproate monotherapy in an SRI-intolerant OCD patient.

1 reference

7 January 2021

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

1 reference

7 January 2021

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?

1 reference

7 January 2021

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

7 January 2021

Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder

1 reference

7 January 2021

Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder

1 reference

7 January 2021

Use of topiramate, a new anti-epileptic as a mood stabilizer.

1 reference

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

7 January 2021

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial

1 reference

7 January 2021

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine

1 reference

7 January 2021

An open trial of topiramate in the treatment of generalized social phobia.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20118

1 reference

4 November 2017

1 reference